Latest filings (excl ownership)
8-K
Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Kristian Humer as Chief Financial Officer
16 Apr 24
8-K
Regulation FD Disclosure
9 Apr 24
8-K
Foghorn Therapeutics Provides Financial Update for 2023 and 2024 Strategic Outlook
7 Mar 24
10-K
2023 FY
Annual report
7 Mar 24
8-K
Regulation FD Disclosure
8 Feb 24
8-K
Departure of Directors or Certain Officers
17 Jan 24
8-K
Foghorn Therapeutics Highlights Clinical Program Updates and Research Progress and Provides Strategic Objectives for 2024
8 Jan 24
8-K
Foghorn Therapeutics Announces CFO Departure
3 Jan 24
10-Q
2023 Q3
Quarterly report
2 Nov 23
8-K
Foghorn Therapeutics Provides Third Quarter 2023 Financial and Corporate Update
2 Nov 23
8-K
Regulation FD Disclosure
8 Sep 23
8-K
Foghorn Therapeutics Announces First Patient Dosed in Phase 1 Combination Study of FHD-286 for Relapsed and/or Refractory AML
31 Aug 23
8-K
Termination of a Material Definitive Agreement
10 Aug 23
8-K
Foghorn Therapeutics Announces Chief Medical Officer Succession
8 Aug 23
10-Q
2023 Q2
Quarterly report
4 Aug 23
8-K
Foghorn Therapeutics Provides Second Quarter 2023 Financial and Corporate Update
4 Aug 23
8-K
Regulation FD Disclosure
28 Jun 23
8-K
Submission of Matters to a Vote of Security Holders
22 Jun 23
8-K
Regulation FD Disclosure
5 Jun 23
S-8
Registration of securities for employees
8 May 23
10-Q
2023 Q1
Quarterly report
8 May 23
8-K
Foghorn Therapeutics Provides First Quarter 2023 Financial and Corporate Update
8 May 23
ARS
2022 FY
Annual report to shareholders
28 Apr 23
DEFA14A
Additional proxy soliciting materials
28 Apr 23
DEF 14A
Definitive proxy
28 Apr 23
8-K
Foghorn Therapeutics Provides an Update on FHD-609
24 Apr 23
10-K
2022 FY
Annual report
9 Mar 23
8-K
Foghorn Therapeutics Provides 2023 Outlook and Full Year 2022 Corporate Update
9 Mar 23
8-K
Regulation FD Disclosure
8 Mar 23
8-K
Foghorn Therapeutics Highlights Recent Clinical and Research Progress and Provides Strategic Objectives for 2023
9 Jan 23
10-Q
2022 Q3
Quarterly report
8 Nov 22
8-K
Foghorn Therapeutics Provides Third Quarter 2022 Financial and Corporate Update
8 Nov 22
8-K
Departure of Directors or Certain Officers
27 Oct 22
8-K
Foghorn Therapeutics Announces New Data Demonstrating BRD9 Degradation in Patient Tumor Biopsies and Discloses New Selective CBP Program
26 Oct 22
8-K
Foghorn Therapeutics Announces Change to Board of Directors
31 Aug 22
8-K
Foghorn Therapeutics Provides Further Update on FHD-286 Phase I Study in Relapsed/Refractory AML/MDS
23 Aug 22
8-K
Departure of Directors or Certain Officers
17 Aug 22
UPLOAD
Letter from SEC
17 Aug 22
8-K
Foghorn Therapeutics Provides Second Quarter 2022 Financial and Corporate Update
9 Aug 22
10-K/A
2021 FY
Annual report (amended)
9 Aug 22
Latest ownership filings
4
Kristian Humer
17 Apr 24
3
Kristian Humer
17 Apr 24
4
Fanny Cavalie
12 Mar 24
SC 13G/A
FMR LLC
9 Feb 24
4
ADRIAN GOTTSCHALK
25 Jan 24
4
Alfonso Quintas Cardama
25 Jan 24
4
Fanny Cavalie
25 Jan 24
4
Carlos Costa
25 Jan 24
4
Steven F. Bellon
25 Jan 24
4
Michael LaCascia
25 Jan 24
4
Allan Reine
17 Jan 24
4
IAN F SMITH
12 Dec 23
4
Samuel Agresta
13 Sep 23
4
Alfonso Quintas Cardama
13 Sep 23
3
Alfonso Quintas Cardama
13 Sep 23
4
Samuel Agresta
18 Aug 23
4
ADRIAN GOTTSCHALK
18 Aug 23
144
Notice of proposed sale of securities
16 Aug 23
4
B LYNNE PARSHALL
22 Jun 23
4
Thomas J. Jr. Lynch
22 Jun 23
4
Douglas G. Cole
22 Jun 23
4
IAN F SMITH
22 Jun 23
4
Scott Biller
22 Jun 23
4
Adam Koppel
22 Jun 23
4
SIMBA GILL
22 Jun 23
4
Michael Mendelsohn
22 Jun 23
4
ADRIAN GOTTSCHALK
31 May 23
4
ADRIAN GOTTSCHALK
22 Feb 23
SC 13G/A
FMR LLC
9 Feb 23
4
Samuel Agresta
30 Jan 23
4
Fanny Cavalie
30 Jan 23
4
Steven F. Bellon
30 Jan 23
4
Carlos Costa
30 Jan 23
4
Michael LaCascia
30 Jan 23
4
ADRIAN GOTTSCHALK
30 Jan 23
4
Allan Reine
30 Jan 23
4
Thomas J. Jr. Lynch
31 Oct 22
3
Thomas J. Jr. Lynch
31 Oct 22
4
ADRIAN GOTTSCHALK
19 Sep 22
4
SIMBA GILL
14 Sep 22